Abstract

Cationic antimicrobial peptides (CAPs), including taxonomically diverse defensins, are innate defense molecules that display potent antimicrobial and immunomodulatory activities. Specific CAPs have also been shown to possess anticancer activities; however, their mechanisms of action are not well defined. Recently, the plant defensin NaD1 was shown to induce tumour cell lysis by directly binding to the plasma membrane phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). The NaD1-lipid interaction was structurally defined by X-ray crystallography, with the defensin forming a dimer that binds PI(4,5)P2 via its cationic β2-β3 loops in a 'cationic grip' conformation. In this study, we show that human β-defensin 3 (HBD-3) contains a homologous β2-β3 loop that binds phosphoinositides. The binding of HBD-3 to PI(4,5)P2 was shown to be critical for mediating cytolysis of tumour cells, suggesting a conserved mechanism of action for defensins across diverse species. These data not only identify an evolutionary conservation of CAP structure and function for lipid binding, but also suggest that PIP-binding CAPs could be exploited for novel multifunction therapeutics.

Highlights

  • Occurring antimicrobial peptides (AMPs) are an important component of host innate immunity, representing the first line of chemical defense against invading pathogens

  • We demonstrate for the first time that a human cationic AMPs (CAPs), HBD-3, binds phosphoinositides and that the interaction with propidium iodide (PI)(4,5)P2 in particular, is critical for the tumour cell killing activity of this defensin

  • The precise molecular basis underlying these functions of HBD-3, the anticancer activity, remains unclear

Read more

Summary

Introduction

Occurring antimicrobial peptides (AMPs) are an important component of host innate immunity, representing the first line of chemical defense against invading pathogens. Defensins and many other CAPs display diverse functions and mechanisms of action, including multimodal and multitarget microbicidal effects, and immunomodulatory activities [3,4,5,6,7]. A number of CAPs have been found to exhibit specific anticancer activity against solid and/or hematological tumours, and represent a potential therapeutic strategy to counter current issues of adverse side-effects and multidrug resistance [8,9,10]. Baxter et al [12] recently demonstrated PI(4,5)P2 specificity and tumour cell cytotoxicity for the related tomato defensin TPP3, suggesting a shared molecular target and mechanism of action for these defensins

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call